3 February 2021

Rutherford Health plc

Rutherford Health announces start of radiotherapy services in Liverpool

Rutherford Health plc (the "Company" or "Group" or "Rutherford") is pleased to announce that its centre in Liverpool, the Rutherford Cancer Centre North West, has been approved by the Care Quality Commission to treat patients with radiotherapy.

The centre opened last summer and to date has been offering patients Systemic Anti-Cancer Therapy (SACT) services which include chemotherapy, immunotherapy, targeted therapies symptom control as well as blood tests, oncology nurse consultation, supportive therapies and diagnostic services. Commencement of radiotherapy treatment will significantly enhance the centre's offering.

The Rutherford Cancer Centre North West provides a significant step forward for cancer care in the region as it is equipped with an Elekta Unity MR-Linac in addition to an Elekta Versa HD linac. The Elekta Unity MR Linac combines a linear accelerator with an integrated Philips MR Scanner and is at the forefront of radiotherapy technology providing the highest quality image guided radiotherapy with online adaptive re-planning.

It is currently expected that high energy proton beam therapy equipment will be installed at the centre later this year with first patients treated in 2022, which will make the centre one of the most advanced cancer therapy facilities in Europe.

Mike Moran, CEO of Rutherford Health, said: "We are delighted to bring MR Linac to Liverpool. It heralds a significant step forward for advanced cancer care services in the region and will be the first in the Liverpool City Region. Our network of cancer centres continues to play a key role in providing cancer care across the UK, especially in relation to precision radiotherapy."

Services at the Rutherford Cancer Centre North West will be accessible to private patients under medical insurance, self-pay patients and to NHS patients where NHS contracts are in place.

The Directors of the Company accept responsibility for the contents of this announcement.

VIEW ANNOUNCEMENT ON AQUIS